{"abstract": "Novartis has become the first company to win approval for a copy of Johnson & Johnson\u2019s Eprex anemia treatment, allowing it to offer cheaper versions to Europeans.", "web_url": "https://www.nytimes.com/2007/09/01/business/01anemia.html", "snippet": "Novartis has become the first company to win approval for a copy of Johnson & Johnson\u2019s Eprex anemia treatment, allowing it to offer cheaper versions to Europeans.", "lead_paragraph": "Novartis has become the first company to win approval for a copy of Johnson & Johnson\u2019s Eprex anemia treatment, allowing it to offer cheaper versions to Europeans.", "print_section": "C", "print_page": "4", "source": "The New York Times", "multimedia": [], "headline": {"main": "Generic Anemia Drug Allowed", "kicker": null, "content_kicker": null, "print_headline": "Generic Anemia Drug Allowed", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2007-09-01T04:00:00+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Bloomberg News", "person": [{"firstname": "Bloomberg", "middlename": null, "lastname": "News", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/e126befd-9c5a-5ea7-a9b9-d1704a9d2d3c", "word_count": 241, "uri": "nyt://article/e126befd-9c5a-5ea7-a9b9-d1704a9d2d3c"}